The Executive Director, Rare Disease Marketing will be a key commercial leader driving the successful U.S. launch of a potential new therapy for a rare neurodevelopmental disorder, while shaping the broader strategy for Acadia's rare disease franchise. This highly visible role will lead the development and execution of innovative U.S. HCP marketing strategies, ensuring seamless integration across functions and delivering a best-in-class customer experience. As the strategic lead, the Executive Director will partner cross-functionally with Consumer Marketing, Sales, Market Access, Patient Services, Medical Affairs, and Commercial Operations to build brand positioning, disease awareness, and core messaging that accelerate diagnosis and treatment. The role will also oversee HCP campaign development, non-personal promotion, digital ecosystem strategy, KOL engagement, congress planning, and vendor/agency partnerships. This individual will be instrumental in translating market insights into actionable strategies, defining success metrics, and ensuring flawless pre-launch, launch, and post-launch execution. In addition, the Executive Director will support global expansion efforts in Rett syndrome and prepare for future pipeline opportunities, such as Prader-Willi syndrome. This is a rare opportunity to make a meaningful impact in the lives of patients and families affected by devastating rare neurological disorders while advancing Acadia's leadership in rare disease innovation.